Xuanzhu Biopharmaceutical Co., Ltd.
23
3
5
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 23 trials
100.0%
+13.5% vs industry average
26%
6 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations
Role: lead
Drug-drug Interaction Study of Rifampin and Anaprazole Sodium
Role: lead
A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
Role: lead
A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer
Role: lead
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
Role: lead
Food Effect and Mass Balance Study of XZP-3621 Tablets
Role: lead
A Study of XZB-0004 in Patients With Solid Tumors
Role: lead
A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Role: lead
A Study of the Absorption, Metabolism and Excretion of [14C]XZP-3621 in Human
Role: lead
A Study of KM501 in Patients With Solid Tumors
Role: lead
A Study of KM602 in Patients With Advanced Solid Tumors
Role: lead
To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS
Role: lead
A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis
Role: lead
Drug-drug Interaction Study of XZP-3621 Tablet
Role: lead
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
Role: lead
A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC
Role: lead
A Clinical Trial of XZP-3287 for Material Balance
Role: lead
A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.
Role: lead
A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib
Role: lead
A Clinical Trial of XZP-6019 Tablets in Healthy Subjects
Role: lead